-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A study published today in the top journal BMJ aims to assess the risk of mental health disorders among survivors of the acute phase of COVID-19
COVID-19
The cohort for this cohort study included 153,848 people who survived the first 30 days of SARS-CoV-2 infection , as well as two control groups: a contemporary group with no evidence of SARS-CoV-2 (n=5637840) and a historical control group (n=5637840) n=5859251)
Infect
The covid-19 group developed anxiety disorders (hazard ratio 1.
The covid-19 group also showed neurocognitive decline (1.
diagnosis
These findings suggest that individuals who survive the acute phase of COVID-19 are at increased risk of developing a range of mental health disorders .
These findings suggest that individuals who survive the acute phase of COVID-19 are at increased risk of developing a range of mental health disorders
Original source:
Yan Xie, et al.